At a time when COVID-19 cases are increasing drastically in India, Sun Pharmaceutical Industries has launched Favipiravir (200 mg) tablets.
Favipiravir Tablet is useful for the treatment of COVID-19 mild to moderate cases. As of now, it is the only oral anti-viral treatment approved in India for treating the mild to moderate COVID-19 patients. Favipiravir (200 mg) tablets will be sold in India under the brand FluGuard.
CEO of India Business at Sun Pharma, Kirti Ganorkar said
With over 50,000 COVID-19 positive cases daily in India, there is an urgent need to provide more treatment options to healthcare professionals,
We are launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This is in line with our continuous efforts to support India”s pandemic response,
Sun Pharma is the topmost pharmaceutical company in India and also the world’s fourth-largest speciality generic pharmaceutical company.
Presently Sun Pharma is delivering its products for patients and customers in over 100 countries. Its global presence is well supported by manufacturing units spread across 6 continents. And all of them are approved by multiple regulatory agencies with respective countries.
Also, Read: Russia Claims World’s First COVID-19 Vaccine
To avoid fatal deaths due to the Coronavirus, the company has stated that it will work closely with the government of India and the medical community to ensure the availability of FluGuard to the COVID-19 affected patients across the country at the earliest. The company has also confirmed that the stocks of FluGuard will be made available in the market by this weekend. The price of each Favipiravir (200 mg) tablet is economical at ₹.35/- per tablet.
Hopefully, the availability and the affordable cost of Favipiravir (200 mg) tablet will ensure the decline of the death rates in India and save the people from the pandemic.